Science 37 Receives 2025 Clinical Trials Arena Site Innovation Award for R&D Leadership
MORRISVILLE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today...
Year: 2025
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Represents second complex respiratory therapeutic product approval in Q4 2025BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc....
NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share
BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or “the Company”), a technology-driven company building...
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,...
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against...
Alkeus Pharmaceuticals Appoints Renowned Retina Specialist and Biotech Executive Carlos Quezada-Ruiz, M.D., F.A.S.R.S., as Chief Medical Officer
Dr. Quezada-Ruiz, an internationally recognized ophthalmologist and experienced drug development leader, has joined the company as Chief Medical Officer.Seemi Khan,...
Predictive Oncology Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded...
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and immune activation in heavily pretreated...
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to...
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required...
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
Vancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
Ra’anana, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company developing...
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical...
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10,...
Nkarta to Participate in Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered...
Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery
Pluristyx to lead a new public-private consortium with 9 other industry leaders to establish global standards for non-animal drug testing...
Ventyx Provides Clinical and Corporate Updates
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding...
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old...